Not burnt by its disappointment with Alzheimer’s candidate solanezumab, US pharma major Eli Lilly (NYSE: LLY) has announced a worldwide agreement with Anglo-Swedish company AstraZeneca (LSE: AZN) on another drug focused on the amyloid beta pathway.
The two companies are to co-develop MEDI1814, an antibody selective for amyloid-beta 42, which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer’s disease (AD).
"MEDI1814 has a unique mechanism among antibodies in clinical development"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze